Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 6/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829654 | 0.87 | CCR4 (0.49) | CCR4FLT3CACNA2D1CYP3A4KDM4E | |
| SCHEMBL17829794 | 0.87 | CCR4 (0.44) | CCR4FLT3CACNA2D1CYP3A4KDM4E | |
| SCHEMBL17833263 | 0.81 | CCR4 (0.51) | CCR4FLT3CACNA2D1 | |
| SCHEMBL17829572 | 0.80 | CCR4 (0.47) | CCR4FLT3CACNA2D1KCNH3 | |
| SCHEMBL17829627 | 0.80 | CCR4 (0.63) | CCR4FLT3CACNA2D1 | |
| SCHEMBL17829618 | 0.80 | CCR4 (0.53) | CCR4FLT3CACNA2D1 | |
| SCHEMBL17829620 | 0.79 | CCR4 (0.76) | CCR4FLT3CACNA2D1CYP3A4KDM4E | |
| SCHEMBL17829807 | 0.78 | CCR4 (0.72) | CCR4FLT3CACNA2D1CYP3A4KDM4E | |
| SCHEMBL17833269 | 0.78 | CCR4 (0.41) | CCR4FLT3CACNA2D1CYP3A4KDM4E | |
| SCHEMBL17833017 | 0.77 | CCR4 (0.47) | CCR4FLT3CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | CCR4 4472/4885FLT3 870/4885CACNA2D1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.